Gufic Biosciences Limited — Vancomycin Exporter Profile
Indian Pharmaceutical Exporter · #7 for Vancomycin · $5.2M export value · DGFT Verified
Gufic Biosciences Limited is the #7 Indian exporter of Vancomycin with $5.2M in export value and 165 verified shipments. Gufic Biosciences Limited holds a 5.6% market share in Vancomycin exports across 12 countries. The company exports 5 pharmaceutical products worth $12.6M across 4 therapeutic categories.
Gufic Biosciences Limited — Vancomycin Export Profile: Buyers & Destinations
Where Does Gufic Biosciences Limited Export Vancomycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| GERMANY | $2.1M | 47 | 59.7% |
| HUNGARY | $375.3K | 43 | 10.7% |
| SRI LANKA | $295.5K | 27 | 8.4% |
| MALAYSIA | $260.4K | 6 | 7.4% |
| COLOMBIA | $147.0K | 7 | 4.2% |
| MYANMAR | $119.4K | 6 | 3.4% |
| CANADA | $103.1K | 4 | 2.9% |
| KENYA | $49.0K | 9 | 1.4% |
| LITHUANIA | $33.5K | 3 | 1.0% |
| NEPAL | $24.9K | 4 | 0.7% |
Gufic Biosciences Limited exports Vancomycin to 12 countries. The largest destination is GERMANY accounting for 59.7% of Gufic Biosciences Limited's Vancomycin shipments, followed by HUNGARY (10.7%) and SRI LANKA (8.4%). These destinations reflect Gufic Biosciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Vancomycin from Gufic Biosciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| HANSE SERVICE INTERNATIONALE | GERMANY | $1.6M | 34 |
| TO THE ORDER OF | MALAYSIA | $587.1K | 62 |
| HANSE SERVICE | GERMANY | $329.5K | 8 |
| SLIM PHARMACEUTICALS (PVT) LTD, | SRI LANKA | $188.2K | 16 |
| HANSE SERVICE INTERNATIONALE, | GERMANY | $187.6K | 5 |
| TO THE ORDER OF BANK ISLAM MALAYSIA | MALAYSIA | $150.0K | 3 |
| LIFELINE CO LTD | MYANMAR | $61.3K | 2 |
| SGS PHARMA MAG. KFT, | HUNGARY | $57.0K | 2 |
| EVENSEN CONTINENTAL CORPORATION AN | COLOMBIA | $50.0K | 1 |
| EVENSEN CONTINENTAL CORPORATION AND | COLOMBIA | $44.8K | 3 |
Gufic Biosciences Limited supplies Vancomycin to 25 buyers globally. The largest buyer is HANSE SERVICE INTERNATIONALE (GERMANY), followed by TO THE ORDER OF (MALAYSIA) and HANSE SERVICE (GERMANY). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Vancomycin Export Value and How Much Does Gufic Biosciences Limited Contribute?
India exported $58.7M worth of Vancomycin through 3,071 shipments from 318 suppliers to 140 countries, serving 743 buyers globally. Gufic Biosciences Limited contributes $5.2M to this total, accounting for 5.6% of India's Vancomycin exports. Gufic Biosciences Limited ships Vancomycin to 12 countries through 25 buyers.
What Is the Average Shipment Value for Gufic Biosciences Limited's Vancomycin Exports?
Gufic Biosciences Limited's average Vancomycin shipment value is $31.3K per consignment, based on 165 shipments totaling $5.2M. The largest destination is GERMANY (59.7% of Gufic Biosciences Limited's Vancomycin exports).
How Does Gufic Biosciences Limited Compare to Other Indian Vancomycin Exporters?
Gufic Biosciences Limited ranks #7 among 318 Indian Vancomycin exporters with a 5.6% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($15.9M), STRIDES PHARMA SCIENCE LIMITED ($11.0M), GLAND PHARMA LIMITED ($5.4M). Gufic Biosciences Limited processed 165 shipments to 12 destination countries.
What Vancomycin Formulations Does Gufic Biosciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| VANCOMYCIN DR. EBERTH 500MG (VANCOMYCIN | $555.9K | 12 |
| VANCOMYCIN DR. EBERTH 1000MG (VANCOMYCIN | $550.0K | 11 |
| VANCOMYCIN HYDROCHLORIDE POWDER 500 MG ( | $100.0K | 2 |
| VAMOCIN 500 INJ (VANCOMYCIN HYDROCHLORID | $70.4K | 2 |
| VAMOCIN (VANCOMYCIN HYDROCHLORIDE INJECT | $68.1K | 3 |
| VAMOCIN 500 INJ (VANCOMYCIN HYDROCHLORI | $50.0K | 1 |
| VANCOMYCIN 500 MG INJ - VANCOMYCIN HYD | $50.0K | 1 |
| VANCOMYCIN DR. EBERTH 500MG VANCOMYCINHCL POWDER OF INJ 500 MG PACK SIZE-1X10?S, 8,250 PACKS, 82,500 VIALS | $50.0K | 1 |
| VANCOMYCIN DR. EBERTH 1000MG VANCOMYCINHCL POWDER OF INJ 1000 MG PACK SIZE-1X10?S 7783 PACKS, 77830 VIALS | $50.0K | 1 |
| VANCOMYCIN DR. EBERTH 1000MG VANCOMYCINHCL POWDER OF INJ 1000 MG PACK SIZE-1X10?S 9981 PACKS 99810 VIALS | $50.0K | 1 |
Gufic Biosciences Limited exports 112 distinct Vancomycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is VANCOMYCIN DR. EBERTH 500MG (VANCOMYCIN with 12 shipments worth $555.9K.
Regulatory Requirements: Exporting Vancomycin to Key Markets
What Gufic Biosciences Limited must comply with to export Vancomycin to its top destination countries
Germany — BfArM/EMA
Approval Process
Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.
Timeline: 12–18 months via Decentralized Procedure
GMP & Export Requirements
EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence
Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory
Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Gufic Biosciences Limited Compare to Nearest Vancomycin Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | GLAND PHARMA LIMITED | $5.4M | 108 | 7 | $50.0K |
| 6 | ASPIRO PHARMA LIMITED | $5.4M | 149 | 19 | $36.1K |
| 7 | GUFIC BIOSCIENCES LIMITED ★ | $5.2M | 165 | 12 | $31.3K |
| 5 | GLAND PHARMA LTD | $3.0M | 59 | 7 | $50.0K |
| 8 | LUPIN LIMITED | $2.5M | 49 | 1 | $50.0K |
Gufic Biosciences Limited ranks #7 among 318 Indian Vancomycin exporters. Average shipment value of $31.3K compared to the market average of $184.6K. The closest competitors by value are GLAND PHARMA LIMITED and ASPIRO PHARMA LIMITED.
Which Indian Ports Ship Vancomycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 406 | 13.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 395 | 12.9% |
| NHAVA SHEVA SEA (INNSA1) | 221 | 7.2% |
| DELHI AIR | 135 | 4.4% |
| BANGALORE ACC (INBLR4) | 134 | 4.4% |
| BANGALORE AIR | 133 | 4.3% |
| BANGALORE ICD (INWFD6) | 119 | 3.9% |
| HYDERABAD ACC (INHYD4) | 116 | 3.8% |
Geopolitical & Trade Policy Impact on Gufic Biosciences Limited's Vancomycin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Gufic Biosciences. The Israel-Iran conflict has led to increased tensions in the Red Sea, a vital shipping route for Indian exports. Houthi attacks in the region have disrupted maritime logistics, resulting in higher shipping costs and potential delays. These disruptions could impact Gufic's supply chain efficiency and delivery timelines, necessitating strategic adjustments to maintain export commitments.
In the United States, recent tariff policies have introduced uncertainties for pharmaceutical imports. While health products have been exempt from tariffs, there have been threats to impose significant increases to encourage domestic production. Such measures could affect Indian exporters, including Gufic, by altering the competitive landscape and potentially reducing market share in the U.S. (lemonde.fr)
Conversely, U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to fill gaps left by Chinese suppliers. Gufic could leverage this opportunity to expand its footprint in markets seeking alternative sources for pharmaceutical products.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. The directive mandates stringent serialization and traceability measures to prevent counterfeit medicines from entering the supply chain. Gufic's adherence to these regulations is essential to maintain and grow its presence in the EU market.
Gufic Biosciences Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Gufic's Indore facility, which commenced production in October 2024, is designed to meet WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards. This facility has achieved 30% capacity utilization for FY26 and is on track for EBITDA breakeven. Such compliance not only facilitates market access but also enhances the company's reputation for quality and reliability. (scanx.trade)
However, recent tax-related penalties highlight the importance of robust internal controls and adherence to financial regulations. Gufic's proactive approach in appealing these penalties demonstrates its commitment to regulatory compliance and financial integrity.
About Gufic Biosciences Limited
Gufic Biosciences Limited exports 5 products worth $12.6M. Beyond Vancomycin, top products include Teicoplanin, Strip, Meropenem, Amphotericin. View the complete Gufic Biosciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Vancomycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Vancomycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Gufic Biosciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 165 individual customs records matching Gufic Biosciences Limited exporting Vancomycin, covering 112 formulations to 12 countries via 25 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 140+ countries, 743+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Vancomycin Export Data from Gufic Biosciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Gufic Biosciences Limited's Vancomycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Gufic Biosciences Limited
Full Company Profile →
5 products · $12.6M total trade · 4 categories
Vancomycin Stats
Company Overview
Top Products by Gufic Biosciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Gufic Biosciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Vancomycin. For current shipment-level data, contact TransData Nexus.